Kornimate/medical-research-clean huggingface dataset:
development of ai model for renal tumor diagnosis using ct and lab tests

Conditions: Renal Tumors

Summary: this multi-center retrospective study aims to develop a multimodal artificial intelligence diagnostic model using preoperative contrast-enhanced ct images and routine laboratory parameters from patients with renal tumors. the model is designed to assist clinicians in accurately predicting the pathological subtypes of renal tumors preoperatively, enabling detailed diagnoses and advancing precision medicine.


Eligibility criteria:
inclusion criteria: * underwent renal tumor resection with a complete postoperative pathological report, and the pathological diagnosis is one of the following types: clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, renal angiomyolipoma, or renal oncocytoma. * complete and available four-phase contrast-enhanced ct scans prior to surgery. * complete and available routine laboratory test results prior to surgery. exclusion criteria: * incomplete ct data or poor image quality that affects diagnostic analysis. * a time interval of more than three months between imaging or laboratory testing and pathological diagnosis. * patients diagnosed with fat-rich renal angiomyolipoma (aml). * pathological diagnosis indicating the coexistence of two or more pathological types of renal tumors.
prospective study of cerebral palsy scoliosis

Conditions: Cerebral Palsy; Scoliosis

Summary: this is a prospective, multi-centre study that will be looking at two groups of males and females over the course of their operative treatment for cerebral palsy (cp) scoliosis and the years following that treatment. the first group the study will be looking at is those individuals who undergo surgery for cp scoliosis. the second group will be those individuals who do not undergo surgical treatment for cp scoliosis, either because the family declines surgery or surgery is not recommended during the course of study participation.


Eligibility criteria:
inclusion criteria: * between the ages of 8 and 18 years * diagnosis of cerebral palsy with total body involvement * coronal curve greater than 40 degrees or a kyphotic curve greater than 50 degrees on sitting film will be included * growing rod treatment will also be included exclusion criteria: * previous operated scoliotic spine deformity * diagnosis of rett's syndrome * concomitant lower extremity surgery (within 3 months of spinal fusion) * cornelia de lange syndrome or any pervasive genetic disorder whose effects are due to much more than the static cortical injury * ambulatory spastic diplegic without upper extremity impairment or speech, swallowing or other involvement

Keywords: cerebral palsy scoliosis children
measuring the concurrent validity of the upper limb use ratio with accelerometers in an ecological situation after stroke.

Conditions: Cerebrovascular Accident

Summary: the purpose of this stufy is to measure the concurrent validity of the upper limb use ratio with accelerometers in an ecological situation after stroke.

the first visit will be used to present the study and potential risks to patients, obtain their consent and collect clinical data. a second visit is planned for the patients who meet the eligibility requirements, to carry out activities in ecological situation.

Eligibility criteria:
inclusion criteria: * subject with hemiparesis following stroke * subject participating in ecological activities during occupational therapy sessions * adult subject aged 18 or over * subject informed of study participation and not objecting to participation exclusion criteria: * other neurological or musculoskeletal disorders limiting use of upper limbs * pregnant or breast-feeding woman, * failure to obtain consent, * non-affiliation with a social security scheme, * persons under court protection, * person protected by law (under guardianship or curatorship) * participant in another research project with an exclusion period still ongoing.

Keywords: learned non-use accelerometer neurorehabilitation stroke
a randomised single centre study to compare the long-term wear characteristics of marathon™ and enduron™ polyethylene cup liners in primary total hip replacement

Conditions: Osteoarthritis; Post-traumatic Arthritis; Collagen Disorders; Avascular Necrosis; Traumatic Femoral Fractures; Nonunion of Femoral Fractures; Congenital Hip Dysplasia; Slipped Capital Femoral Epiphysis

Summary: the purpose of this study is to compare the performance and compare the wear characteristics of two polyethylene cup liners, marathon™ and enduron™, in the treatment of patients with hip joint disease requiring a total hip replacement. patients who enter the study will be randomly allocated to one of the polyethylene cup liners, marathon™ or enduron™ and will be evaluated at regular intervals using clinical and x-ray assessments.

the original protocol intended to perform clinical assessment using the harris hip score, merle d'aubigne score and ucla activity level rating at 6 months, 1 year, 2 years, 3 years, 4 years, 5 years and 10 years post-operative. merle d'aubigne score evaluation was removed per amendment 2. however, protocol-specified data collected included only the linear and volumetric wear and incidence and pattern of radiological signs at 10 years post surgery. data collected outside of the protocol included oxford hip score and sf-12 for mental and physical well-being at 10 years post surgery and revision for any reason.

Eligibility criteria:
inclusion criteria: i) male or female subjects, aged between 45 and 75 years inclusive. ii) subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained. iii) subjects who, in the opinion of the investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. iv) subjects with non-inflammatory arthritis of the hip who require a primary hip arthroplasty and are considered by the clinical investigator to be suitable for a cemented femoral component and an uncemented acetabular component. v) subjects who have a charnley c classification vi) subjects who have undergone a contralateral hip replacement within past 6 months vii) subjects with a poorly functioning contralateral hip replacement or one which has been identified as requiring revision viii) the first hip replacement scheduled for subjects identified as requiring primary bi-lateral hip replacements which will not be conducted simultaneously (i.e. on the same day). exclusion criteria: i) subjects who, in the opinion of the investigator, have an existing condition that would compromise their participation and follow-up in this study. ii) women who are pregnant. iii) subjects who are known drug or alcohol abusers or with psychological disorders that could effect follow-up care or treatment outcomes. iv) subjects who have participated in a clinical study with an investigational product in the last month.

Keywords: hip cemented
efficacy and safety of remote ischemic conditioning in the treatment of essential hypertension (ricbp-eh)

Conditions: Essential Hypertension

Summary: the purpose of this study is to determine the efficacy and safety of remote ischemic conditioning in the treatment of essential hypertension.

current studies have shown that remote ischemic conditioning can improve vascular endothelial function, inhibit sympathetic nervous system activity and regulate immune and inflammatory reactions. thus it may exert anti-hypertensive effects through multiple mechanisms. the purpose of this study is to investigate the efficacy and safety of remote ischemic conditioning on blood pressure patients with essential hypertension.

Eligibility criteria:
inclusion criteria: 1. age≥18 years, regardless of sex; 2. patients with systolic blood pressure ≥140mmhg with or without taking oral antihypertensive drugs 3. signed and dated informed consent is obtained exclusion criteria: 1. secondary hypertension; 2. clinical blood pressure ≥ 180/110 mmhg or 24-hour mean arterial pressure ≥ 170/100 mmhg; 3. severe organ dysfunction or failure; 4. severe hematologic disorders or significant coagulation abnormalities; 5. history of atrial fibrillation or myocardial infarction within 6 months; 6. individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; 7. individuals who will or have received anticoagulant therapy with drugs such as dabigatran, rivaroxaban, warfarin, etc; ; 8. pregnant or lactating women; 9. those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment; 10. other conditions that the researchers think are not suitable for the project.
treatment of stable both-bone midshaft forearm fractures in children

Conditions: Fracture; Forearm; Midshaft; Child; Treatment

Summary: we create a randomized clinical trial between the treatment with above elbow armcast alone and the treatment of above elbow in combination with a short arm cast for stable midshaft both-bone forearm fractures.

children who arrive at the emergency unit with a stable both-bone midshaft forearm fracture will be asked to join the trial. if the fracture will be stable during reposition in the operating room, a randomization between 2 kinds of plaster treatment will be done. outpatient clinic visits till a follow-up of 6 months. during these visits we will investigate: consolidation and dislocation on x-ray, function of both arms, complains in daily living and complications.

Eligibility criteria:
inclusion criteria: * both-bone forearm fracture * age \< 16 years * dislocation * stable exclusion criteria: * fracture older than 1 week * no informed consent * refracture * open fracture (gustillo 2 and 3)

Keywords: fracture forearm midshaft child treatment
effect of exercise on disease activity and cardiovascular risk factors in patients with ankylosing spondylitis

Conditions: Ankylosing Spondyliti

Summary: background: exercise is recommended as a cornerstone in the treatment of ankylosing spondylitis together with medication. last years, increased risk of cardiovascular diseases in patient with inflammatory diseases is reported, probably caused by inflammation and increased prevalence of traditional risk factors. in both healthy adults and other patient groups, cardiorespiratory and muscular strength exercises have been shown to have a positive effect on inflammation as well as on cardiovascular risk factors. to our knowledge this has not been shown in patients with ankylosing spondylitis. objective: the aim of this study is to investigate the effects of a cardiorespiratory and muscular strength exercise program on disease activity and cardiovascular risk factors in patients with ankylosing spondylitis


Eligibility criteria:
inclusion criteria: * diagnosis of ankylosing spondylitis, confirmed by a rheumatologist * age, 18-70 years * not using tnf-α medication or steady medication for ≥3 months * disease activity ≥2.1 on ankylosing spondylitis disease activity score defined as high disease activity * not participated in a structured cardiorespiratory or muscle strengthening exercise program during the last year (\>60 min once per week), including large amounts of brisk walking (\>120 min per week) exclusion criteria: * known cardiovascular disease * severe comorbidity which involves reduced exercise capacity * not able to participate in weekly exercises sessions in oslo * pregnancy
reduced fluence photodynamic therapy (pdt) with visudyne in combination with lucentis for age-related macular degeneration

Conditions: Age-Related Maculopathy; Choroidal Neovascularization

Summary: in this pilot study the researchers will evaluate the safety and efficacy of 50% reduced fluence pdt combination therapy with ranibizumab. the researchers hope to gain information regarding the use of reduced fluence pdt combination therapy. the information gained from this pilot study may prompt further definitive studies comparing the safety and efficacy of both standard fluence pdt combination therapy, reduced fluence pdt combination therapy, and ranibizumab monotherapy. the study will compare the use of combination therapy with ranibizumab and verteporfin pdt to ranibizumab alone in patients with exudative age-related macular degeneration (amd). all patients will receive three consecutive monthly treatments with ranibizumab. patients will be randomized 1:1:1 to 3 groups. patients randomized to group 1 will receive only ranibizumab. patients randomized to group 2 will also receive one treatment with reduced fluence (50% fluence) verteporfin pdt at day 0. patients randomized to group 3 will also receive one treatment with standard fluence verteporfin pdt. all patients will also be evaluated for possible retreatment with ranibizumab and verteporfin pdt according to established criteria. thirty patients will be recruited from one u.s. sites. randomization will occur at the time of entry into the study. follow-up will continue until month 12 (from day 0) in all subjects.


Eligibility criteria:
inclusion criteria: 1. male or female patients \> 50 years of age. 2. patients with primary subfoveal cnv secondary to amd documented on ivfa and/or oct. 3. patient with bcva of 20/40 to 20/320 in the study eye using early treatment diabetic retinopathy study (etdrs) charts. see definition of etdrs charts. 4. if both eyes are eligible, only one eye will be evaluated in the study. the eye with lesser visual acuity will be selected as the study eye. 5. patients must be able and willing to provide written informed consent. exclusion criteria: 1. patients receiving prior treatment in the study eye with verteporfin, any focal laser photocoagulation, vitrectomy, or intravitreous injection of antiangiogenic medications, including triamcinolone, pegaptanib, bevacizumab, or ranibizumab. 2. neovascular membrane from any other retinal disease such as myopic degeneration, histoplasmosis, retinal angiomatous proliferation, or other ocular inflammatory disease. 3. choroidal neovascular membrane greater than 9 disc diameters in size. 4. previous posterior vitrectomy in the study eye. 5. concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the study period. 6. pregnant women or premenopausal women not using adequate contraception. 7. history of allergy to fluorescein, visudyne, lucentis. 8. inability to comply with study or follow up procedures.

Keywords: ranibizumab lucentis verteporfin visudyne photodynamic therapy
nanoliposomal irinotecan (nal-iri, onivyde®) in combination with tas-102 (lonsurf®) in refractory solid tumors

Conditions: Refractory Solid Tumors

Summary: the study is to explore the combination of nal-iri and tas-102, which is expected to be an effective regimen that could be applied to various cancers

primary objectives * to determine the maximum tolerated dose (mtd) of nal-iri (onivyde®) in combination with tas-102 (lonsurf®) * to evaluate the toxicity profile of the combination therapy secondary objectives * to evaluate the preliminary efficacy of the combination therapy of nal-iri (onivyde®) and tas-102 (lonsurf®) * to study the pharmacokinetics of the combination therapy a phase 1 study with a classical 3 + 3 dose escalation design. the target population is patients who have pathologically confirmed malignant solid tumors with no standard treatment available.

Eligibility criteria:
inclusion criteria: 1. ages between 20 to 70 years old 2. histologically or cytologically confirmed malignant solid tumors which are advanced or metastatic, have failed standard treatment or have no standard treatment currently available 3. ecog performance status 0 or 1 4. normal ecg or ecg without any clinically significant findings 5. adequate hematologic parameters, and hepatic and renal function i. white blood cell (wbc) count 3000/μl and absolute neutrophil count (anc) 1500/μl ii. platelet counts 100,000/μl without platelet transfusion within 14 days iii. hemoglobin level 10 g/dl iv. serum total bilirubin- within normal range v. serum albumin 3.0 g/dl vi. serum alanine aminotransferase (alt) 3 x the upper limit of normal (uln) vii. serum creatinine 1.5 x uln exclusion criteria: 1. received prior nal-iri (onivyde®) or tas-102 (lonsurf®) therapy 2. known hypersensitivity to any of the components of nal-iri, other liposomal products, fluoropyrimidines or leucovorin 3. have liver cirrhosis with child-pugh b or child-pugh c 4. with active cns metastasis (indicated by clinical symptoms, cerebral edema, steroid requirement, or progressive growth) 5. with clinically significant gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea \> grade 1 6. life expectancy of less than 3 months 7. use any anti-cancer or investigational product within 14 days prior to the first date of study dosing 8. history of any second malignancy in the latest 5 years except curatively treated non-melanoma skin cancer or treated cervical carcinoma in situ 9. uncontrolled inter-current illness including, but not limited to, ongoing or active infection requiring antibiotic treatment, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia, and psychiatric illness or social situation that would preclude study compliance 10. homozygous for the ugt1a1 28 allele (ta7/ta7), homozygous for ugt1a1 6 allele (a/a), or double heterozygous for both ugt1a1 28 allele (ta6/ta7) and ugt1a1 6 allele (g/a) (only for dose-finding phase) 11. pregnant or breastfeeding women
endoscopic ultrasound guided fine needle biopsy (eus-fnb-sc) using a novel fork needle

Conditions: Pancreatic Cancer

Summary: this is a clinical trial to compare two needles used in biopsy techniques to acquire tissue from pancreatic cancer. the hypothesis is that the tissue yield, as measured by tumor dna and cellular material is superior for flexible needle biopsy (fnb) compared with conventional fine needle aspiration (fna). specifically, fnb will increase the proportion of cases in which sufficient dna is obtained to allow genomic profiling and whole exome sequencing.

this is a single-blinded randomized controlled trial with paired evaluation of conventional fna needle versus fnb needle stratified by lesion location (pancreas head tumor versus pancreas body/tail). a minimum of 4 passes ( 2 with each needle) will be performed from all the lesions. after each pass of needle, the on-site cytopathologists will evaluate the adequacy and the degree of the pathological changes in the obtained material. based on the information provided by the onsite cytopathologists, the endosonographer will repeat the fna until enough histological material is obtained to confirm a diagnosis. patients will be assessed immediately after procedure and during the first 30 days with a follow-up.

Eligibility criteria:
inclusion criteria: * male and female patients who are 18 years old or older and are referred for the evaluation of pancreatic mass lesion. * international normalized ratio (inr) less than 1.5 and platelet count of more than 50,000. * medically stable to undergo sedation for eus. * signed informed consent exclusion criteria: * medical condition that preclude the patient from having a therapeutic procedure regardless of the eus finding * pregnant patients
health coaching to promote physical activity for coronary heart disease prevention

Conditions: Coronary Disease; Atherosclerosis

Summary: the purpose of this study is to evaluate the efficacy of motivational interviewing-based coaching to increase physical activity to achieve guidelines recommendations for cardiovascular disease prevention.

cardiovascular diseases are the main cause of death in developed countries. epidemiological studies have shown that a sedentary lifestyle is associated with an increased risk of cardiovascular diseases, mainly related to classical risk factors (obesity, diabetes, hypertension). international guidelines recommend, because of that, a minimum of 30 minutes per day at least 5 days per week of moderate physical activity for primary and secondary cardiovascular disease prevention. physical inactivity is an increasing public health problem in developed countries. it is known that clinical advice has a poor efficacy to increase levels of physical activity on individuals and new strategies need to be developed. coaching is a strategy of personal help that is being widely and successfully used in business world. it consists of an structured and individualized process of assistance to people to promote cognitive changes needed to achieve behavioural changes. it can be a complementary method to information and sanitary education emphasizing on consciousness and responsibility of the patient and is now starting to be used in medical practice. the purpose of the study is to define usefulness of an strategy based on coaching techniques to promote physical activity practice and healthy lifestyle on individuals with known coronary heart disease or cardiovascular risk factors.

Eligibility criteria:
inclusion criteria: * patients wiht coronary risk factors or known ischaemic heart disease defined as sedentary (\<600met-min/week). exclusion criteria: * bundle branch block or pacemaker rhythm * limitation or contraindication to moderate physical activity (fast walking) * unstable clinical situation * communication difficulties due to language or sensorial deficiencies. * lack of informed consent

Keywords: secondary prevention health promotion behavioral medicine exercise therapy
comparsion of wt and snp techniques of eus-fnb in pancreatic solid mass (wesp-psm)

Conditions: Pancreatic Neoplasms; Diagnoses Disease

Summary: the purpose of this study is to compare the diagnosis accuracy between of wet suction (ws) technique and standard negative pressure (snp) technique in eus-fnb by 22g eus procore fine needle biopsy（fnb）device for solid pancreatic lesions.

this is a multi-center, single-blind, randomized, controlled trial. two hundred and ninety six patients with solid pancreatic lesions referred for eus guided fine needle biopsy will be randomly assigned to two groups. for group a which will be used with 22g eus procore fine needle biopsy device, the pass sequence is ws-snp-ws-snp technique. for group b with 22g eus procore fine needle biopsy device, the pass sequence is snp-ws-snp-ws. all procedures will be performed by experienced echo-endoscopists, and the patients and assessors (cytologists and pathologists) will be blinded during the entire study. the primary outcome measure is the diagnosis yield. secondary outcome measures are specimen quality.

Eligibility criteria:
inclusion criteria: 1. informed consent 2. subjects over 18 years old 3. imaging examination (ultrasound, ct or mri) diagnosed or suspected solid pancreatic mass more than 1cm exclusion criteria: 1. unable or refused to sign informed consent 2. suspended anticoagulant/antiplatelet therapy 3. being pregnant or breastfeeding 4. cystic lesions of the pancreas 5. coagulation disorders (plt \ 1.5) 6. a history of mental illness 7. other medical conditions that are not suitable for fnb puncture

Keywords: endoscopic ultrasound endoscopic ultrasound guided fnb